Escherichia coli Modulator of Drug Activity B (MdaB) Has Different Enzymological Properties to Eukaryote Quinone Oxidoreductases

Clare F. Megarity, David J Timson

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Some quinone oxidoreductases exhibit negative cooperativity towards inhibitors. In human NQO1, this is mediated by flexibility around glycine-150. Here we investigated the eubacterial orthologue, Modulator of Drug Activity B (MdaB) to determine if it shows cooperativity towards substrates or inhibitors and to investigate molecular recognition of the inhibitor, dicoumarol. Like human NQO1, MdaB did not show cooperativity towards substrates. However, unlike NQO1, it was only weakly inhibited by dicoumarol. Alanine-127 in MdaB is the structurally equivalent residue to Gly-150 in human NQO1. With the intention of increasing protein flexibility in MdaB, this alanine was altered to glycine. This change did not increase cooperativity towards inhibitors or NADPH. Based on structural alignment to NQO1 in complex with dicoumarol, an asparagine in the active site was changed to alanine to reduce steric hindrance. This change resulted in enhanced inhibition by dicoumarol, but the inhibition was not cooperative. Both changes were then introduced simultaneously. However, the additional increase in flexibility afforded by the change to glycine did not enable negative cooperativity towards dicoumarol. These results have implications for the evolution of quinone oxidoreductases and their potential use as biocatalysts.

Original languageEnglish
Article numbere1900135
JournalHelvetica Chimica Acta
Volume102
Issue number8
DOIs
Publication statusPublished - 10 Jul 2019

Fingerprint

Dicumarol
Eukaryota
Oxidoreductases
Escherichia coli
Alanine
Glycine
Pharmaceutical Preparations
Asparagine
NADP
Catalytic Domain
benzoquinone
Enzymes
Proteins

Bibliographical note

This is the peer reviewed version of the following article: Megarity, C. . and Timson, D. . (2019), Escherichia coli Modulator of Drug Activity B (MdaB) has different enzymological properties to eukaryote quinone oxidoreducatases. Helv. Chim. Acta., which has been published in final form at https://onlinelibrary.wiley.com/doi/abs/10.1002/hlca.201900135. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.

Keywords

  • quinone oxidoreductase
  • dicoumarol
  • protein engineering
  • cooperativity
  • enzyme catalysis

Cite this

@article{3532c363b734438aa54ccec022680235,
title = "Escherichia coli Modulator of Drug Activity B (MdaB) Has Different Enzymological Properties to Eukaryote Quinone Oxidoreductases",
abstract = "Some quinone oxidoreductases exhibit negative cooperativity towards inhibitors. In human NQO1, this is mediated by flexibility around glycine-150. Here we investigated the eubacterial orthologue, Modulator of Drug Activity B (MdaB) to determine if it shows cooperativity towards substrates or inhibitors and to investigate molecular recognition of the inhibitor, dicoumarol. Like human NQO1, MdaB did not show cooperativity towards substrates. However, unlike NQO1, it was only weakly inhibited by dicoumarol. Alanine-127 in MdaB is the structurally equivalent residue to Gly-150 in human NQO1. With the intention of increasing protein flexibility in MdaB, this alanine was altered to glycine. This change did not increase cooperativity towards inhibitors or NADPH. Based on structural alignment to NQO1 in complex with dicoumarol, an asparagine in the active site was changed to alanine to reduce steric hindrance. This change resulted in enhanced inhibition by dicoumarol, but the inhibition was not cooperative. Both changes were then introduced simultaneously. However, the additional increase in flexibility afforded by the change to glycine did not enable negative cooperativity towards dicoumarol. These results have implications for the evolution of quinone oxidoreductases and their potential use as biocatalysts.",
keywords = "quinone oxidoreductase, dicoumarol, protein engineering, cooperativity, enzyme catalysis",
author = "Megarity, {Clare F.} and Timson, {David J}",
note = "This is the peer reviewed version of the following article: Megarity, C. . and Timson, D. . (2019), Escherichia coli Modulator of Drug Activity B (MdaB) has different enzymological properties to eukaryote quinone oxidoreducatases. Helv. Chim. Acta., which has been published in final form at https://onlinelibrary.wiley.com/doi/abs/10.1002/hlca.201900135. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.",
year = "2019",
month = "7",
day = "10",
doi = "10.1002/hlca.201900135",
language = "English",
volume = "102",
journal = "Helvetica Chimica Acta",
issn = "0018-019X",
publisher = "John Wiley & Sons, Ltd",
number = "8",

}

Escherichia coli Modulator of Drug Activity B (MdaB) Has Different Enzymological Properties to Eukaryote Quinone Oxidoreductases. / Megarity, Clare F.; Timson, David J.

In: Helvetica Chimica Acta, Vol. 102, No. 8, e1900135, 10.07.2019.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Escherichia coli Modulator of Drug Activity B (MdaB) Has Different Enzymological Properties to Eukaryote Quinone Oxidoreductases

AU - Megarity, Clare F.

AU - Timson, David J

N1 - This is the peer reviewed version of the following article: Megarity, C. . and Timson, D. . (2019), Escherichia coli Modulator of Drug Activity B (MdaB) has different enzymological properties to eukaryote quinone oxidoreducatases. Helv. Chim. Acta., which has been published in final form at https://onlinelibrary.wiley.com/doi/abs/10.1002/hlca.201900135. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.

PY - 2019/7/10

Y1 - 2019/7/10

N2 - Some quinone oxidoreductases exhibit negative cooperativity towards inhibitors. In human NQO1, this is mediated by flexibility around glycine-150. Here we investigated the eubacterial orthologue, Modulator of Drug Activity B (MdaB) to determine if it shows cooperativity towards substrates or inhibitors and to investigate molecular recognition of the inhibitor, dicoumarol. Like human NQO1, MdaB did not show cooperativity towards substrates. However, unlike NQO1, it was only weakly inhibited by dicoumarol. Alanine-127 in MdaB is the structurally equivalent residue to Gly-150 in human NQO1. With the intention of increasing protein flexibility in MdaB, this alanine was altered to glycine. This change did not increase cooperativity towards inhibitors or NADPH. Based on structural alignment to NQO1 in complex with dicoumarol, an asparagine in the active site was changed to alanine to reduce steric hindrance. This change resulted in enhanced inhibition by dicoumarol, but the inhibition was not cooperative. Both changes were then introduced simultaneously. However, the additional increase in flexibility afforded by the change to glycine did not enable negative cooperativity towards dicoumarol. These results have implications for the evolution of quinone oxidoreductases and their potential use as biocatalysts.

AB - Some quinone oxidoreductases exhibit negative cooperativity towards inhibitors. In human NQO1, this is mediated by flexibility around glycine-150. Here we investigated the eubacterial orthologue, Modulator of Drug Activity B (MdaB) to determine if it shows cooperativity towards substrates or inhibitors and to investigate molecular recognition of the inhibitor, dicoumarol. Like human NQO1, MdaB did not show cooperativity towards substrates. However, unlike NQO1, it was only weakly inhibited by dicoumarol. Alanine-127 in MdaB is the structurally equivalent residue to Gly-150 in human NQO1. With the intention of increasing protein flexibility in MdaB, this alanine was altered to glycine. This change did not increase cooperativity towards inhibitors or NADPH. Based on structural alignment to NQO1 in complex with dicoumarol, an asparagine in the active site was changed to alanine to reduce steric hindrance. This change resulted in enhanced inhibition by dicoumarol, but the inhibition was not cooperative. Both changes were then introduced simultaneously. However, the additional increase in flexibility afforded by the change to glycine did not enable negative cooperativity towards dicoumarol. These results have implications for the evolution of quinone oxidoreductases and their potential use as biocatalysts.

KW - quinone oxidoreductase

KW - dicoumarol

KW - protein engineering

KW - cooperativity

KW - enzyme catalysis

UR - http://www.scopus.com/inward/record.url?scp=85068933590&partnerID=8YFLogxK

U2 - 10.1002/hlca.201900135

DO - 10.1002/hlca.201900135

M3 - Article

VL - 102

JO - Helvetica Chimica Acta

JF - Helvetica Chimica Acta

SN - 0018-019X

IS - 8

M1 - e1900135

ER -